Page 63 - 2017 V1 InsideOut

Not an actual patient.
*
*BeneFix was approved February 11, 1997.1
YOUR EXPERIENCE. A DECIDING FACTOR.
CONFIDENCE
• BeneFix – the Recombinant Factor IX you’ve turned to for more than 20 years* CONTROL OF BLEEDING EPISODES
• BeneFix can be used in previously untreated patients, previously treated patients, and patients undergoing surgery2
CUSTOMIZATION
• BeneFix offers flexible dosing with a wide range of vial sizes to meet your patients’ needs2
CHOICE
• BeneFix is approved for both on-demand and preventive dosing regimens so your patients can infuse when needed2
Selected Safety Information
• BeneFix is contraindicated in patients who have manifested life-threatening, immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including hamster protein.
• Hypersensitivity reactions, including anaphylaxis, have been reported with BeneFix. Closely monitor patients for signs and symptoms of acute anaphylaxis, particularly during the early phases of initial exposure to the product. Immediately discontinue the administration of the product and initiate appropriate treatment if symptoms occur.
Please see Indication and full Important Safety Information for BeneFix on first page and brief summary of full Prescribing Information on the last page of this advertisement.
REFERENCES: 1. Center for Biologics Evaluation and Research, US Food and Drug Administration, US Department of Health and Human Services. CBER Approval Letter, Coagulation Factor IX (Recombinant), Genetics Institute, Inc. http://www.fda.gov/BiologicsBloodVaccines/ BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm057039.htm. Published February 11, 1997. Accessed July 9, 2016. 2. BeneFix® Coagulation Factor IX (Recombinant) [Prescribing Information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2015.